SRR8943046
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- INTERFERON_ALPHA_RESPONSE+0.400
- ANGIOGENESIS+0.390
- COAGULATION+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.340
- INTERFERON_GAMMA_RESPONSE+0.330
- PROTEIN_SECRETION+0.320
- KRAS_SIGNALING_UP+0.290
- ALLOGRAFT_REJECTION+0.280
- APICAL_JUNCTION+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.290
- DNA_REPAIR-0.230
- KRAS_SIGNALING_DN-0.200
- XENOBIOTIC_METABOLISM-0.160
- PEROXISOME-0.140
- ESTROGEN_RESPONSE_LATE-0.130
- FATTY_ACID_METABOLISM-0.120
- ADIPOGENESIS-0.110
- ANDROGEN_RESPONSE-0.110
- BILE_ACID_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.848 |
| 2 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.844 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.830 |
| 4 | MBCProject_0698_T1_RNA | — | A | 0.819 |
| 5 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.819 |
| 6 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.816 |
| 7 | C3L-03462 | — | cohortA1 | 0.810 |
| 8 | SRR975589 | — | — | 0.809 |
| 9 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.807 |
| 10 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |